MyFinsight
Home
About
Contact
alny: the income statement
Download
Download image
Non USOr Europe
$9,757K
Europe
$22,346K
US
$20,727K
Non USOr Europe
$4,742K
Europe
$18,706K
US
$50,426K
Non USOr Europe
$6,917K
Europe
$19,678K
US
$12,480K
Non USOr Europe
$43,012K
Europe
$111,944K
US
$530,347K
OXLUMO
$52,830K
GIVLAARI
$73,874K
ONPATTRO
$39,075K
Amvuttra
$685,303K
Other Collaborations
$2,596K
Regeneron
Pharmaceuticals Incorporation
$22,542K
Roche
$326,604K
Rare
$126,704K
TTR
$724,378K
Royalty
$46,202K
Collaborations
$351,742K
Product
$851,082K
Total revenues
$1,249,026K
(149.35%↑ Y/Y)
Income (loss) from
operations
$367,982K
(578.49%↑ Y/Y)
Total operating costs
and expenses
$881,044K
(52.48%↑ Y/Y)
Defined benefit pension
plans, net of tax
-$53K
(-76.67%↓ Y/Y)
Foreign currency
translation gains (losses)
$6,993K
Unrealized gains on
marketable securities
$1,131K
(-87.54%↓ Y/Y)
Benefit from (provision
for) income taxes
-$12,115K
(-516.75%↓ Y/Y)
Income (loss) before
income taxes
$238,969K
(319.92%↑ Y/Y)
Total other expense,
net
-$129,013K
(-306.24%↓ Y/Y)
Interest income
$28,681K
(-10.78%↓ Y/Y)
Selling, general and
administrative
$322,076K
(45.74%↑ Y/Y)
Research and development
$358,814K
(32.44%↑ Y/Y)
Cost of
collaborations and royalties
$2,923K
(-25.53%↓ Y/Y)
Cost of goods sold
$197,231K
(140.58%↑ Y/Y)
Net other
comprehensive income (loss)
$8,177K
Net income (loss)
$251,084K
(325.05%↑ Y/Y)
Other expense, net
-$74,150K
(-151.12%↓ Y/Y)
Loss related to
convertible debt
$39,146K
Interest expense
$44,398K
(29.15%↑ Y/Y)
Comprehensive income (loss)
$259,261K
(354.78%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ALNYLAM PHARMACEUTICALS, INC. (ALNY)